The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain

European Psychiatry

Volumn 23, Issue 1, 2008, Pages 1-7

  Ciudad, Antonio ^a   Haro, Josep María ^b   Alonso, Jordi ^c   Bousoño, Manuel ^d   Suárez, David ^b   Novick, Diego ^e   Gilaberte, Inmaculada ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b Hospital S Juan de Dios   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY OF OVIEDO   (Spain)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agents; Health care surveys; Outcome assessment; Prospective studies; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SPAIN; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE SURVEYS; HUMANS; LONGITUDINAL STUDIES; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SPAIN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38949165469     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.09.008     Document Type: Article

References (26)

1. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., and Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67 (2006) 453-460
2. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., and Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6 (2006) 8
3. Citrome L., Jaffe A., Levine J., and Lindenmayer J.P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 66 (2005) 1512-1516
4. Coley K.C., Carter C.S., DaPos S.V., Maxwell R., Wilson J.W., and Branch R.A. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 60 (1999) 850-856
5. Conley R.R., Love R.C., Kelly D.L., and Bartko J.J. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 156 (1999) 863-868
6. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158 (2001) 518-526
7. Dossenbach M., Arango-Davila C., Silva Ibarra H., Landa E., Aguilar J., Caro O., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66 (2005) 1021-1030
8. Dossenbach M., Dyachkova Y., Pirildar S., Anders M., Khalil A., Araszkiewicz A., et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 21 (2006) 251-258
9. Dossenbach M., Erol A., el Mahfoud Kessaci M., Shaheen M.O., Sunbol M.M., Boland J., et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65 (2004) 312-321
10. Dossenbach M.R., Kratky P., Schneidman M., Grundy S.L., Metcalfe S., Tollefson G.D., et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 62 Suppl 2 (2001) 28-34
11. Droulout T., Liraud F., and Verdoux H. Relationships between insight and medication adherence in subjects with psychosis. L'Encephale 29 (2003) 430-437 (in French)
12. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., and Lieberman J.A. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163 (2006) 2090-2095
13. Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 12 Suppl 1 (1997) S37-S42
14. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 107 (2003) 222-232
15. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 107 (2003) 16-23
16. Haro J.M., Novick D., Belger M., and Jones P.B. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 21 (2006) 41-47
17. Haro J.M., Suarez D., Novick D., Brown J., Usall J., and Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17 (2007) 235-244
18. Ho B.C., Miller D., Nopoulos P., and Andreasen N.C. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 60 (1999) 658-663
19. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 161 (2004) 1-56 second edition
20. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
21. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., and Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Res 57 (2002) 209-219
22. Schooler N.R. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 67 Suppl 5 (2006) 19-23
23. Sullivan G., Wells K.B., Morgenstern H., and Leake B. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 152 (1995) 1749-1756
24. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40 (2002) 630-639
25. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155 (2001) 230-233
26. Weiss K.A., Smith T.E., Hull J.W., Piper A.C., and Huppert J.D. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophrenia Bull 28 (2002) 341-349